Advertisement

Specialty News

July 01, 2015
June 26, 2015
While the adverse effects of chemotherapy are well known, cognitive impairment—also known as “chemo brain” or “chemo fog”—has only recently gained...
Integrative Medicine
MORE
April 01, 2015
March 31, 2015
FDA has approved blinatumomab (Blincyto—Amgen) for the treatment of patients with Philadelphia chromosome–negative B-cell precursor acute...
New Drug
MORE
April 01, 2015
March 30, 2015
FDA has approved lenvatinib (Lenvima—Eisai), a new oral treatment option for patients with locally recurrent or metastatic differentiated thyroid...
New Drug
MORE
April 01, 2015
March 30, 2015
Panobinostat (Farydak—Novartis) received accelerated FDA approval to treat patients with multiple myeloma who have received at least two prior...
New Drug
MORE
April 01, 2015
March 30, 2015
On March 6, FDA approved the first biosimilar product for U.S. patients, filgrastim-sndz (Zarxio—Sandoz). Approval was based on its similarity to...
Zarxio was approved based on its similarity to Neupogen
MORE
April 01, 2015
March 27, 2015
Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system (CNS) affecting the brain, spinal cord, and optic nerves. In...
Specialty Pharmacy Section
MORE
December 01, 2014
November 25, 2014
Ledipasvir and sofosbuvir (Harvoni—Gilead), a newly approved once-daily oral combination tablet, is being touted as a “game changer” by many...
New Drug
MORE
September 01, 2014
August 22, 2014
Idelalisib (Zydelig—Gilead Sciences), an oral therapy for the treatment of three B-cell blood cancers, has received FDA approval. The new drug...
New Drug
MORE
July 01, 2014
June 27, 2014
Specialty pharmacy has always prided itself on providing patient-centered, high-touch care that focuses on both therapy efficacy and safety. This...
Specialty Pharmacy Section
MORE
July 01, 2014
June 26, 2014
Personalized medicine is not a new concept. The idea of tailoring therapy to one’s unique genetic composition—or pharmacogenomics—has been studied...
Specialty Pharmacy Section
MORE

Pages